Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (3) : 284-286     DOI: 10.1007/s11684-009-0062-1
Research articles |
Role of nitric oxide in biological effects of vascular endothelial growth factor
Qigong LIU M D , Yan ZENG , Jiani LIU , Shan YE , Yongdong LI , Zaiying LU M D ,
Department of Internal Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;
Download: PDF(72 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  To evaluate the role of nitric oxide in the biological effects of vascular endothelial growth factor (VEGF) and the possible mechanism of VEGF, the in vitro cultured vascular endothelial cells of rabbit aorta were divided into control group, VEGF-treated group and VEGF+ N-nitro-L-arginine methyl ester (L-NAME)-treated group. The absorbance (A) value of vascular endothelial cells and the levels of prostaglandin (PGI2), endothelin-1 (ET-1) and von Willebrand factor (vWF) in the supernatant were observed by water-soluble tetrazolium salt assay, radioimmunoassay and enzyme-linked immunosorbent assay. The A values and PGI2 in VEGF-treated group and VEGF+L-NAME-treated group were higher than those in control group (P<0.05 and P<0.01). The ET-1 and vWF were significantly decreased in VEGF-treated group and VEGF+L-NAME-treated group compared with the control (P<0.05 and P<0.01). These results indicate that VEGF could promote the proliferation and secretion of PGI2 and inhibit the secretion of ET-1 and vWF in vascular endothelial cells and that L-NAME could inhibit the effect of VEGF partially. Nitric oxide is an important mediator in the process of stimulating proliferation and regulating secretion of vascular endothelial cells by VEGF.
Keywords vascular endothelial growth factor      nitric oxide      N-nitro-L-arginine methyl ester      vascular endothelial cells      
Issue Date: 05 September 2009
URL:     OR
Kusumanto Y H, van Weel V, Mulder N H, Smit A J, van den Dungen J J, Hooymans J M, Sluiter W J, Tio R A, Quax P H, Gans R O, Dullaart R P, Hospers G A. Treatment with intramuscular vascular endothelial growthfactor gene compared with placebo for patients with diabetes mellitusand critical limb ischemia: a double-blind randomized trial. Hum Gene Ther, 2006, 17(6): 683―691

doi: 10.1089/hum.2006.17.683
Qian H S, Liu P, Huw L Y, Orme A, Halks-Miller M, Hill S M, Jin F, Kretschmer P, Blasko E, Cashion L, Szymanski P, Vergona R, Harkins R, Yu J, Sessa W C, Dole W P, Rubanyi G M, Kauser K. Effective treatment of vascular endothelial growth factorrefractory hindlimb ischemia by a mutant endothelial nitric oxidesynthase gene. Gene Ther, 2006, 13(18): 1342―1350

doi: 10.1038/
Testa U, Pannitteri G, Condorelli G L. Vascular endothelial growth factors in cardiovascularmedicine. J Cardiovasc Med (Hagerstown), 2008, 9(12): 1190―1221
Ylä-Herttuala S, Rissanen T T, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status ofclinical applications in cardiovascular medicine. J Am Coll Cardiol, 2007, 49(10): 1015―1026

doi: 10.1016/j.jacc.2006.09.053
Bougioukas I, Didilis V, Ypsilantis P, Giatromanolaki A, Sivridis E, Lialiaris T, Mikroulis D, Simopoulos C, Bougioukas G. Intramyocardial injection of low-dose basic fibroblastgrowth factor or vascular endothelial growth factor induces angiogenesisin the infarcted rabbit myocardium. CardiovascPathol, 2007, 16(2): 63―68

doi: 10.1016/j.carpath.2006.08.006
Fuchs S, Dib N, Cohen B M, Okubagzi P, Diethrich E B, Campbell A, Macko J, Kessler P D, Rasmussen H S, Epstein S E, Kornowski R. A randomized, double-blind,placebo-controlled, multicenter, pilot study of the safety and feasibilityof catheter-based intramyocardial injection of AdVEGF121 in patientswith refractory advanced coronary artery disease. Catheter Cardiovasc Interv, 2006, 68(3): 372―378

doi: 10.1002/ccd.20859
Stewart D J, Hilton J D, Arnold J M, Gregoire J, Rivard A, Archer S L, Charbonneau F, Cohen E, Curtis M, Buller C E, Mendelsohn F O, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler P D, Rasmussen H S. Angiogenic gene therapy in patients with nonrevascularizableischemic heart disease: a phase 2 randomized, controlled trial ofAdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther, 2006, 13(21): 1503―1511

doi: 10.1038/
Liu Q G, Lu Z Y, Zhou H L, Yan J, Zhang W D. The mechanical study of vascular endothelialgrowth factor on the prevention of restenosis after angioplasty. J Tongji Med Univ, 2001, 21(3): 195―198
Deiner C, Schwimmbeck P L, Koehler I S, Loddenkemper C, Noutsias M, Nikol S, Schultheiss H P, Ylä-Herttuala S, Pels K. Adventitial VEGF165 gene transfer preventslumen loss through induction of positive arterial remodeling afterPTCA in porcine coronary arteries. Atherosclerosis, 2006, 189(1): 123―132

doi: 10.1016/j.atherosclerosis.2005.12.008
Sun Y M, Liu Q G, Zheng X Y. Effects of VEGF transduction through a Foley’scatheter on local vascular endothelial cell growth. Zhongguo Zuzhi Gongcheng Yanjiu Yu Linchuang Kangfu, 2008, 12(39): 7797―7800 (in Chinese)
Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä A, Vanninen E, Mussalo H, Kauppila E, Simula S, Närvänen O, Rantala A, Peuhkurinen K, Nieminen M S, Laakso M, Ylä-Herttuala S. Safety and feasibility of catheter-based local intracoronary vascularendothelial growth factor gene transfer in the prevention of postangioplastyand in-stent restenosis and in the treatment of chronic myocardialischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation, 2003, 107(21): 2677―2683

doi: 10.1161/01.CIR.0000070540.80780.92
Li H G, Forstermann U. Nitric oxide in the pathogenesisof vascular disease. J Pathol, 2000, 190(3): 244–254

doi: 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8
Hood J D, Meininger C J, Ziche M, Granger H J. VEGF upregulates ecNOS message, protein and NO production in humanendothelial cells. Am J Physiol, 1998, 274 (Heart Circ Physiol 43): H1054―1058
Ziche M, Morbidelli L, Choudhuri R, Zhang H T, Donnini S, Granger H J, Bicknell R. Nitric oxide synthase liesdownstream from vascular endothelial growth factor-induced but notbasic fibroblast growth factor-induced angiogenesis. J Clin Invest, 1997, 99(11): 2625―2634

doi: 10.1172/JCI119451
[1] Geqing XIA, Chaoying WU. Expression of inducible nitric oxide synthase in trophoblasts and deciduas in early medical abortion[J]. Front Med Chin, 2009, 3(2): 216-219.
[2] Qigong LIU, Honglian ZHOU, Yan ZENG, Shan YE, Jiani LIU, Zaiying LU. Mechanism of vascular endothelial growth factor on the prevention of restenosis after angioplasty[J]. Front Med Chin, 2009, 3(2): 177-180.
[3] Zhizhen LI, Fangping LI, Jianhong YE, Li YAN, Zuzhi FU. Effects of resistin on insulin signaling in endothelial cells[J]. Front Med Chin, 2009, 3(2): 136-140.
[4] ZHAN Rong, YU Qinghong, HUANG Haobo. Effect of arsenic trioxide on proliferation and apoptosis of U266 cells and its relationship with the expression variation of VEGF[J]. Front. Med., 2008, 2(4): 356-360.
[5] WANG Lin, LIU Yalan, XU Jianbo, TIAN Yuan, WU Heshui. Protective effect of N-acetylcysteine against lipopolysaccharide injury in hepatocytes of neonatal mice[J]. Front. Med., 2008, 2(2): 182-185.
[6] TANG Zhongzhi, LI Junyao, YANG Jianhong. Relationship of endothelial nitric oxide synthase gene polymorphism with blood pressure, lipid profile and blood glucose level[J]. Front. Med., 2008, 2(2): 178-181.
[7] LI Xin, CHENG Chun, CHEN Mengling, GAO Shangfeng, ZHAO Jian, NIU Shuqiong, SHEN Aiguo. Developmental expression of CAPON and Dexras1 in spinal cord of rats[J]. Front. Med., 2008, 2(1): 75-81.
[8] WU Jun, LIN Jinchao, HE Zhaochu, OU Biru, GUO Haisen. Effect of hyperlipidemia on endothelial VCAM-1 expression and the protective role of fenofibrate[J]. Front. Med., 2007, 1(4): 356-358.
Full text